Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 34 min ago
Peer-reviewedCC BY 4.0Cureus

Long-Term Real-World Effectiveness and Safety of Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura: A Multicenter Retrospective Follow-Up Study in Poland

6 affiliations
  1. 1Sferocyt Scientific Society at the Department of Paediatric Oncology, Haematology and Transplantology, Medical University of Warsaw, Warsaw, POL
  2. 2Department of Paediatrics, Medical University of Silesia, Katowice, POL
  3. 3Department of Paediatric Oncology and Haematology, Jagiellonian University Medical College, Krakow, POL
  4. 4Department of Paediatrics, Oncology and Haematology, Medical University of Lodz, Lodz, POL
  5. 5Department of Paediatric Oncology, Haematology and Transplantology, Poznan University of Medical Sciences, Poznan, POL
  6. 6Department of Paediatric Oncology, Haematology and Transplantology, Medical University of Warsaw, Warsaw, POL

Abstract

Background

Congenital thrombotic thrombocytopenic purpura (cTTP) is an ultrarare, inherited thrombotic microangiopathy caused by severe ADAMTS13 deficiency. Recombinant ADAMTS13 (rADAMTS13) provides targeted enzyme replacement, offering an alternative to plasma-based prophylaxis. Although clinical trials have demonstrated encouraging outcomes, evidence regarding long-term effectiveness and safety in routine clinical practice remains limited. This study evaluated extended hematological outcomes, acute thrombotic thrombocytopenic purpura (TTP) events, treatment continuity, and safety during rADAMTS13 prophylaxis.

Methods

This multicenter retrospective observational study included 10 patients with cTTP treated at 5 specialist centers in Poland. Nine patients belonged to a previously published cohort, and one additional patient was included. All had previously received fresh frozen plasma (FFP) and subsequently received intravenous rADAMTS13 at 40 IU/kg every two weeks. Clinical records and standardized physician questionnaires were reviewed through May 2026. Laboratory parameters were evaluated at pretreatment baseline, an initial on-treatment assessment, and extended follow-up. Follow-up lasted approximately 2 to 4 years in the original cohort and 11 months in the additional patient.

Results

All 10 patients continued regular rADAMTS13 prophylaxis without permanent treatment discontinuation or regimen modification. Mean platelet counts were 201.3 ± 93.2 × 10⁹/L at baseline, 252.0 ± 50.5 × 10⁹/L initially, and 193.1 ± 35.6 × 10⁹/L at extended follow-up. All patients had platelet counts within the reference interval at the latest assessment, compared with seven at baseline. Mean lactate dehydrogenase decreased from 239.7 ± 78.1 to 183.8 ± 25.7 U/L. Two patients (20%) experienced clinically diagnosed acute TTP episodes associated with intercurrent infections and required supplementary treatment. Incomplete event-specific laboratory documentation prevented independent verification against standardized criteria. No new strokes or clinically documented renal deterioration were reported. No ADAMTS13 inhibitors were detected in May 2026, and no serious adverse events attributed to rADAMTS13 were documented.

Conclusions

Extended rADAMTS13 prophylaxis was associated with favorable hematological findings at the available assessments, sustained treatment continuity, and an encouraging safety and tolerability profile. These observations provide reassuring real-world evidence supporting its potential value in the long-term management of cTTP. Nevertheless, infection-associated acute TTP events demonstrate the importance of continued clinical surveillance and timely access to additional treatment. Larger prospective studies are needed to confirm long-term effectiveness and safety.

Related

  1. Effectiveness and Patient Compliance of a Needle-Free Injection System in Controlled Ovarian Stimulation in IVF Cycles: A Real-World, Investigator-Initiated, Retrospective, Multicenter, Observational Study
    Manish Banker, Manika Khanna, Baiju P Ahammed +2
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Effectiveness of prenatal predictors for congenital diaphragmatic hernia on survival to discharge and extracorporeal membrane oxygenation requirement: a retrospective cohort study.
    Emily Rogers, Jack Le Vance, Shashi Naidu +4
    Pediatric surgery internationalPeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMC
  3. Comparative Effectiveness of Single Versus Dual Adjuvant Therapy After Breast-Conserving Surgery in Hormone Receptor-Positive Ductal Carcinoma In Situ: A Multicenter Retrospective Cohort Study
    Yuqiang Huang, Xianqiang Du, Junjing Li +1
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0General medicineCrossref
  4. Real-world effectiveness and safety of low-dose tirzepatide in Japanese people with type 2 diabetes: a multicenter, retrospective, single-arm, observational study—East Shizuoka Tirzepatide (ESTATE) study
    Tatsuya Iwamoto, Nozomu Yamasaki, Shuko Nojiri +12
    Endocrine JournalPeer-reviewedCC BY-NC-NDFull textEndocrinology & metabolismJ-STAGE
  5. Comparative Effectiveness and Safety of Etelcalcetide and Cinacalcet in Hemodialysis Patients with Secondary Hyperparathyroidism: A Multicenter Retrospective Cohort Study
    Engin Onan, Emrah Günay, Derya Basak Tanburoglu +8
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0General medicineCrossref
BibTeX
@article{laguna2026longterm,
  title = {{Long-Term Real-World Effectiveness and Safety of Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura: A Multicenter Retrospective Follow-Up Study in Poland}},
  author = {Aleksandra Laguna and Maria Szczepanska and Danuta Pietrys and Magdalena Wojdalska and Elzbieta Trembecka-Dubel and Milosz Jazdon and Walentyna Balwierz and Pawel Laguna},
  journal = {Cureus},
  year = {2026},
  month = nov,
  doi = {10.7759/cureus.119552},
  url = {https://doi.org/10.7759/cureus.119552},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Long-Term Real-World Effectiveness and Safety of Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura: A Multicenter Retrospective Follow-Up Study in Poland
AU  - Aleksandra Laguna
AU  - Maria Szczepanska
AU  - Danuta Pietrys
AU  - Magdalena Wojdalska
AU  - Elzbieta Trembecka-Dubel
AU  - Milosz Jazdon
AU  - Walentyna Balwierz
AU  - Pawel Laguna
PY  - 2026
DA  - 2026/11/12
JO  - Cureus
DO  - 10.7759/cureus.119552
UR  - https://doi.org/10.7759/cureus.119552
AB  - Background  Congenital thrombotic thrombocytopenic purpura (cTTP) is an ultrarare, inherited thrombotic microangiopathy caused by severe ADAMTS13 deficiency. Recombinant ADAMTS13 (rADAMTS13) provides targeted enzyme replacement, offering an alternative to plasma-based prophylaxis. Although clinical trials have demonstrated encouraging outcomes, evidence regarding long-term effectiveness and safety in routine clinical practice remains limited. This study evaluated extended hematological outcomes, acute thrombotic thrombocytopenic purpura (TTP) events, treatment continuity, and safety during rADAMTS13 prophylaxis.  Methods  This multicenter retrospective observational study included 10 patients with cTTP treated at 5 specialist centers in Poland. Nine patients belonged to a previously published cohort, and one additional patient was included. All had previously received fresh frozen plasma (FFP) and subsequently received intravenous rADAMTS13 at 40 IU/kg every two weeks. Clinical records and standardized physician questionnaires were reviewed through May 2026. Laboratory parameters were evaluated at pretreatment baseline, an initial on-treatment assessment, and extended follow-up. Follow-up lasted approximately 2 to 4 years in the original cohort and 11 months in the additional patient.  Results  All 10 patients continued regular rADAMTS13 prophylaxis without permanent treatment discontinuation or regimen modification. Mean platelet counts were 201.3 ± 93.2 × 10⁹/L at baseline, 252.0 ± 50.5 × 10⁹/L initially, and 193.1 ± 35.6 × 10⁹/L at extended follow-up. All patients had platelet counts within the reference interval at the latest assessment, compared with seven at baseline. Mean lactate dehydrogenase decreased from 239.7 ± 78.1 to 183.8 ± 25.7 U/L. Two patients (20%) experienced clinically diagnosed acute TTP episodes associated with intercurrent infections and required supplementary treatment. Incomplete event-specific laboratory documentation prevented independent verification against standardized criteria. No new strokes or clinically documented renal deterioration were reported. No ADAMTS13 inhibitors were detected in May 2026, and no serious adverse events attributed to rADAMTS13 were documented.  Conclusions  Extended rADAMTS13 prophylaxis was associated with favorable hematological findings at the available assessments, sustained treatment continuity, and an encouraging safety and tolerability profile. These observations provide reassuring real-world evidence supporting its potential value in the long-term management of cTTP. Nevertheless, infection-associated acute TTP events demonstrate the importance of continued clinical surveillance and timely access to additional treatment. Larger prospective studies are needed to confirm long-term effectiveness and safety.
SN  - 2168-8184
ER  -